Boston Scientific Analyst Price Targets

Wall Street analyst price targets and consensus rating for Boston Scientific (BSX).

Price Target Range — 5 Quarters

Analyst Consensus — 21 Analysts

19Buy

2Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$71Upside to Avg. PT+59.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 14, 2026	Truist Securities	Richard Newitter	PT Cut	Buy	$57→$51
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Equal-Weight	$48
Oct 5, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$50→$48
Sep 24, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Equal-Weight	$50→$48
Sep 21, 2026	Oppenheimer	Suraj Kalia	PT Cut	Outperform	$85→$65
Sep 17, 2026	Citigroup	Joanne Wuensch	Downgrade	Buy→Neutral	$57→$50
Sep 9, 2026	BTIG	Marie Thibault	PT Cut	Buy	$60→$56
Aug 25, 2026	TD Cowen	Joshua Jennings	Maintained	Buy	$56
Jul 31, 2026	Argus Research	David Toung	Downgrade	Buy→Hold	—
Jul 30, 2026	UBS	Patrick Wood	PT Cut	Buy	$74→$67
Jul 30, 2026	Citigroup	Joanne Wuensch	PT Cut	Buy	$70→$61
Jul 30, 2026	RBC Capital	Kendall Au	PT Cut	Outperform	$85→$70
Jul 30, 2026	TD Cowen	Joshua Jennings	PT Cut	Buy	$61→$56
Jul 30, 2026	Canaccord Genuity	William Plovanic	PT Cut	Buy	$70→$66
Jul 30, 2026	Truist Securities	Richard Newitter	PT Cut	Buy	$62→$57
Jul 30, 2026	Evercore ISI Group	Vijay Kumar	PT Cut	Outperform	$65→$55
Jul 30, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Equal-Weight	$55→$50
Jul 29, 2026	BTIG	Marie Thibault	PT Cut	Buy	$65→$60
Jul 28, 2026	UBS	Patrick Wood	Assumes	Buy	$95→$74
Jul 27, 2026	Oppenheimer	Suraj Kalia	PT Cut	Outperform	$90→$85

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $57 to $51.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Boston Scientific with Equal-Weight Rating, Announces Price Target of $48

Barclays analyst Christopher Pasquale initiates coverage on Boston Scientific (NYSE:BSX) with a Equal-Weight rating and announces Price Target of $48.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $48

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $50 to $48.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $65

Oppenheimer analyst Suraj Kalia maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $85 to $65.

Benzinga Newsdesk

PRO
Citigroup Downgrades Boston Scientific to Neutral, Lowers Price Target to $50

Citigroup analyst Joanne Wuensch downgrades Boston Scientific (NYSE:BSX) from Buy to Neutral and lowers the price target from $57 to $50.

Benzinga Newsdesk

Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts cut targets for CAN, TTAN and BSX, while raising targets for BRZE, VRNS, IMAX, PHVS and CHYM. Ratings largely remained positive.

Avi Kapoor

Boston Scientific Corp

Boston Scientific Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51

PRO
Barclays Initiates Coverage On Boston Scientific with Equal-Weight Rating, Announces Price Target of $48

PRO
Wells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $48

PRO
Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $65

PRO
Citigroup Downgrades Boston Scientific to Neutral, Lowers Price Target to $50

Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday

People Also Watch

People Also Watch

Boston Scientific Corp

Boston Scientific Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTruist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51

PROBarclays Initiates Coverage On Boston Scientific with Equal-Weight Rating, Announces Price Target of $48

PROWells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $48

PROOppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $65

PROCitigroup Downgrades Boston Scientific to Neutral, Lowers Price Target to $50

Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday

People Also Watch

People Also Watch

PRO
Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51

PRO
Barclays Initiates Coverage On Boston Scientific with Equal-Weight Rating, Announces Price Target of $48

PRO
Wells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $48

PRO
Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $65

PRO
Citigroup Downgrades Boston Scientific to Neutral, Lowers Price Target to $50